Saturday, August 13, 2016 5:29:19 PM
Clearly they have inside info relating to their joint products with MNTA, included, but not limited to patent office expectations, Glatopa acceptance and sales, 40 mg likelihood of FDA approval. To sell now suggests a bit of urgency. While the optimists are hoping for good news later this month, which if it were to occur would suggest a slight bump at least in the stock price, selling now appears to make no sense. I can understand the registration to sell so NVS could take advantage of a major pop, but selling shares already suggests that is not their intent or expectation. They certainly are in no need for cash as $55 million has to be chump change for them.
Trying to figure out why now. Could NVS be planning to spin off Sandoz and wants to clean its books of any Sandoz partner holdings prior to a spinoff? Just wildly speculating.
FEATURED Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
